Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC).

@article{Solomon2013SubgroupAO,
  title={Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC).},
  author={Benjamin Solomon and S. Gettinger and G. Riely and S. Gadgeel and H. Nokihara and Ji-Youn Han and T. Hida and M. Satouchi and E. Baldini and S. Siena and N. Yamamoto and L. Horn and V. Tassell and A. Polli and D. Camidge},
  journal={Journal of Clinical Oncology},
  year={2013},
  volume={31},
  pages={8105-8105}
}
  • Benjamin Solomon, S. Gettinger, +12 authors D. Camidge
  • Published 2013
  • Medicine
  • Journal of Clinical Oncology
  • 8105 Background: PROFILE 1007 compared the efficacy and safety of crizotinib with that of standard-of-care chemotherapy in patients with ALK+ NSCLC. Although the study was not designed for formal assessment of patient outcomes on crizotinib vs. PEM or crizotinib vs. DOC, due to later interest, we performed retrospective efficacy and safety analyses of patient subgroups treated with crizotinib or each chemotherapy individually. Methods: Patients with stage IIIB/IV ALK+ NSCLC previously treated… CONTINUE READING
    5 Citations